Docket-Specific Pre-Screen
What we confirm before every Depo-Provera lead is delivered
- Depo-Provera (medroxyprogesterone acetate injectable) use confirmed — injectable, not oral progesterone.
- Duration of use confirmed — 1 year or more of Depo-Provera injections.
- Meningioma (brain tumor) diagnosis confirmed — specifically meningioma, not other brain tumors.
- MRI or imaging confirming meningioma diagnosis referenced where available.
- Diagnosis timeline captured — tumor developed during or after period of Depo-Provera use.
- Pfizer identified as the manufacturer.
- SOL analyzed under discovery rule — runs from diagnosis or knowledge of Depo-Provera connection.
- Not currently represented — confirmed before the lead leaves our system.
SOL Note
Depo-Provera meningioma SOL follows the discovery rule — it runs from the date of diagnosis or the date the claimant knew or should have known of the connection between Depo-Provera and the tumor. The French study publication in 2024 is a reference point for when awareness became widely available.
The Market
The Depo-Provera market
A large French pharmacoepidemiology study published in 2024 found a 5.6-fold increased risk of meningioma in women who used Depo-Provera for more than one year compared to non-users. The finding was consistent across age groups and persisted after controlling for confounders. Pfizer, the manufacturer of Depo-Provera, faces growing litigation on failure-to-warn theories — the product label did not historically warn of meningioma risk despite the long history of hormone-tumor causation research in the endocrinology literature.
The claimant population is women who used Depo-Provera as contraception for a year or longer and subsequently developed meningioma. Diagnosis is typically via MRI ordered for headaches, vision changes, or other neurological symptoms. Meningiomas are often treated surgically when they produce symptoms or reach a threshold size; smaller asymptomatic meningiomas may be monitored.
Why Depo-Provera leads need specialist qualification: the injectable formulation specifically is the focus of the litigation — oral progesterone products are not part of this docket. And the tumor type must specifically be meningioma, not glioblastoma or other primary brain tumors with different causation profiles.
Docket Pipeline
How Depo-Provera leads are qualified
Targeted Acquisition
Only people who matched your exact criteria submitted a form.
Form Pre-Screen
SOL, liability, insurance, and intent — all confirmed before delivery.
Depo-Provera pre-screen confirms injectable formulation, 1+ year use, and specifically meningioma diagnosis.
OTP Phone Verification
The number is real. We proved it before you see it.
Exclusive Delivery
Your CRM. One firm. In under 15 seconds.
Pricing is per qualified lead — never a retainer, never a setup fee, never a monthly commitment. Calculate your all-in cost per signed retainer before you book the call.
Delivery Standards
How every lead arrives and what stands behind it
Every lead passes through four verification steps before delivery. Targeted acquisition drives intake traffic only from people who match your stated criteria. The form pre-screen documents SOL, liability, injury severity, and representation status. OTP phone verification confirms the number is real, active, and in possession of the claimant — not Google Voice, not a disconnected line, not a wrong number. Exclusive delivery places the lead into your CRM inside 15 seconds, locked to your firm ID with a permanent delivery timestamp.
Exclusivity is contractual, not verbal. Your client agreement contains a binding exclusivity term — every lead is sold to exactly one firm and there is no operational path for us to re-deliver it. TrustedForm certificates and Jornaya lead IDs travel with every lead as an independent consent audit trail, timestamped outside our own delivery system. The 48-hour credit exchange is written into your agreement as a contract term, not a return policy: expired SOL at delivery, liability that clearly does not hold based on pre-screen facts, case type mismatch, or represented-at-delivery all qualify without additional documentation. Your intake team’s assessment is sufficient.
Coverage runs in 38 states. Pricing is per qualified lead — no retainer, no setup fee, no monthly commitment. Volume can be paused or reduced with 30 days notice without penalty. Auto-connect puts your intake team on the phone with the claimant within 60 seconds of delivery, which is the single largest lever on contact-to-signed-retainer conversion in every vendor benchmark we have run. Firms routinely report 18–23% close rates on identical leads simply by moving first-call contact from 5 minutes to 60 seconds.
Read the full pipeline breakdown for operational detail on each verification step, or run your numbers with the cost-per-retainer calculator before booking a call.
Frequently Asked Questions
- Depo-Provera leads are priced at $550 per qualified lead as an emerging high-demand docket. No retainer. No setup fee.
Related dockets
The Arrangement
No retainer. No setup fee. No monthly commitment.
Start receiving verified leads in 5–7 days. One firm per case. Every lead OTP-verified. Credit exchange written into your client agreement.